BMS 2 Drug Therapy Achieves Hep C Cure without Interferon

A two drug tablet combination of Bristol-Myers Squibb’s hepatitis C virus (HCV) protease inhibitor asunaprevir (formerly BMS-650032) and HCV NS4A inhibitor daclatasvir (formerly BMS-790052) cleared the virus in one-third of people with hepatitis C genotype 1 who had previously not responded to interferon-based therapy, and both of the trial participants with genotype 1b, according to new research.

This is the first evidence that hepatitis C can be cured without interferon.

Diarrhoea was the most frequently reported side effect.

All patients taking the dual combination remained hepatitis C free 6 months after the end of treatment.